Adma Biologics traded at $2.43 this Friday September 30th, increasing $0.17 or 7.52 percent since the previous trading session. Looking back, over the last four weeks, Adma Biologics gained 10.00 percent. Over the last 12 months, its price rose by 104.20 percent. Looking ahead, we forecast Adma Biologics to be priced at 2.28 by the end of this quarter and at 2.08 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
Daily Change

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Takeda 3,767.00 -9.00 -0.24% 3.60%
Adma Biologics 2.43 0.17 7.52% 104.20%
Adamis Pharmaceuticals 0.20 -0.03 -11.82% -80.35%
Agile Therapeutics 0.30 0.01 4.47% -70.01%
Alnylam Pharmaceuticals 200.16 -9.23 -4.41% 3.88%
BioCryst Pharmaceuticals 12.60 0.24 1.94% -8.23%
Dynavax Technologies 10.44 0.14 1.36% -38.00%
Minerva Neurosciences 9.23 -0.29 -3.05% 484.18%
Novavax 18.20 -0.37 -1.99% -89.98%
Omeros 3.15 -0.07 -2.17% -63.11%

Indexes Price Day Year
USND 10576 -161.89 -1.51% -27.40%

Adma Biologics
ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include ADMA BioManufacturing and Plasma Collection Centers. The Company’s ADMA BioManufacturing segment reflects its immune globulin manufacturing and development operations in Florida. The Plasma Collection Centers segment consists of approximately three plasma collection facilities. Its products include BIVIGAM, ASCENIV and Nabi-HB. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons.